- Home
- SXTC vs CRBP Comparison
SXTC vs CRBP Comparison
Compare SXTC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTC | CRBP |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 134.8M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SXTC | CRBP |
|---|---|---|
| Price | $2.15 | $9.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $46.83 |
| AVG Volume (30 Days) | 55.5K | ★ 178.4K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $99.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $0.03 | $4.64 |
| 52 Week High | $6.98 | $20.56 |
Technical Indicators
Market Signals| Indicator | SXTC | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 52.96 | 61.27 |
| Support Level | $1.92 | $9.08 |
| Resistance Level | $2.37 | $9.69 |
| Average True Range (ATR) | 0.18 | 0.60 |
| MACD | -0.06 | 0.27 |
| Stochastic Oscillator | 35.57 | 73.42 |
Price Performance
Historical ComparisonAbout SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.